HBV Cure vignet
Meeting category
Date(s)
9 Nov 2021 - 10 Nov 2021
Meeting type
Virtual Meeting
Organizer
Silver level sponsor
Sponsor logos
Gilead logo

International Workshop on HBV Cure 2021

Related Enduring Materials

Enduring Materials
Session 1: Therapeutic Advancements for Viral Hepatitis -
Patient Selection for Clinical Trials Based on Drug Class
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
New Data From Combination Trials for Chronic Hepatitis B
Pietro Lampertico, MD, PhD
University of Milan, Italy
New Combination Therapies in Hepatitis Delta Therapy
Jeffrey S. Glenn, MD, PhD
Stanford University, United States
Session 2: Clinical Immunology and Immunotherapy Updates -
What Can We Learn by Deploying Immunological Analysis in Phase II Clinical Trials?
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
TLR-8 Agonist
Simon Fletcher, PhD
Gilead Sciences, United States
Anti-HBs Antibody
Carey Hwang, MD, PhD
Vir Biotechnology, Inc., United States
Immunotherapeutics in the Treatment of Chronic Hepatitis B
Sarah Browne, MD
Altimmune, Inc., United States
VBI-2601: Immunotherapeutic HBV Vaccine Candidate Overview
HBV Immunotherapeutic Vaccines (Lessons from HCV)
Eleanor Barnes, PhD, FRCP, F. Med. Sci.
University of Oxford, United Kingdom
A Novel Approach At Targeting the PD-1/PD-l1 Pathway: PD-l1 Lna
Anna Maria Geretti, MD, PhD, FRCPath
University of Rome, Italy / King's College London, United Kingdom
Session 3: Patient Selection, Stopping Treatment and Biomarkers -
HBsAg Loss: A Predictor of Long-Term Clinical Outcomes
Marion Peters, MD
Northwestern University, United States
Outcomes After NUC Therapy Discontinuation
Markus Cornberg, MD
Hanover Medical School; Centre for Individualised Infection Medicine, Germany
How to Handle Flares in HBV Trials With Novel Agents
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Safety Monitoring during HBV Clinical Trials and after Antiviral Discontinuation
Poonam Mishra, MD, MPH, FAASLD
US Food and Drug Administration, United States
Session 4: Update on Viral Targets for HBV/HDV Therapy -
Biological Insights Taught by Clinical Responses to Novel Hbv/Hdv Drugs
Stephan Urban, PhD
Heidelberg University Hospital, Germany
Core Inhibitors (Capsid Assembly Modulators)
Luisa Stamm, MD, PhD
Assembly Biosciences, United States
Antisense Oligos
Leigh Felton, BSc, PhD
GlaxoSmithKline, United Kingdom
STOP Agents
Matthew McClure, MD
Aligos, United States
Active Site Polymerase Inhibitor Nucleotides (APSINs)
Douglas Mayers, MD
Antios Therapeutics, United States
Update on the Efficacy and Safety of Bulevirtide for Treatment of Chronic HDV
Dmitry Manuilov, MD
Gilead Sciences, Germany